Translating cardioprotection for patient benefit

Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology

Derek J. Hausenloy, Hans Erik Botker, Gianluigi Condorelli, P. Ferdinándy, David Garcia-Dorado, Gerd Heusch, Sandrine Lecour, Linda W. Van Laake, Rosalinda Madonna, Marisol Ruiz-Meana, Rainer Schulz, Joost P G Sluijter, Derek M. Yellon, Michel Ovize

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Despite current therapy, the morbidity and mortality for patients with CHD remains significant. The most important manifestations of CHD arise from acute myocardial ischaemia-reperfusion injury (IRI) in terms of cardiomyocyte death and its long-term consequences. As such, new therapeutic interventions are required to protect the heart against the detrimental effects of acute IRI and improve clinical outcomes. Although a large number of cardioprotective therapies discovered in pre-clinical studies have been investigated in CHD patients, few have been translated into the clinical setting, and a significant number of these have failed to show any benefit in terms of reduced myocardial infarction and improved clinical outcomes. Because of this, there is currently no effective therapy for protecting the heart against the detrimental effects of acute IRI in patients with CHD. One major factor for this lack of success in translating cardioprotective therapies into the clinical setting can be attributed to problems with the clinical study design. Many of these clinical studies have not taken into consideration the important data provided from previously published pre-clinical and clinical studies. The overall aim of this ESC Working Group Cellular Biology of the Heart Position Paper is to provide recommendations for optimizing the design of clinical cardioprotection studies, which should hopefully result in new and effective therapeutic interventions for the future benefit of CHD patients.

Original languageEnglish
Pages (from-to)7-27
Number of pages21
JournalCardiovascular Research
Volume98
Issue number1
DOIs
Publication statusPublished - Apr 1 2013

Fingerprint

Coronary Disease
Cell Biology
Reperfusion Injury
Therapeutics
Myocardial Reperfusion Injury
Cardiac Myocytes
Myocardial Ischemia
Cause of Death
Myocardial Infarction
Clinical Studies
Morbidity
Mortality

Keywords

  • Acute myocardial infarction
  • Cardiac surgery
  • Cardioprotection: Ischaemia
  • Reperfusion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

Translating cardioprotection for patient benefit : Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. / Hausenloy, Derek J.; Erik Botker, Hans; Condorelli, Gianluigi; Ferdinándy, P.; Garcia-Dorado, David; Heusch, Gerd; Lecour, Sandrine; Van Laake, Linda W.; Madonna, Rosalinda; Ruiz-Meana, Marisol; Schulz, Rainer; Sluijter, Joost P G; Yellon, Derek M.; Ovize, Michel.

In: Cardiovascular Research, Vol. 98, No. 1, 01.04.2013, p. 7-27.

Research output: Contribution to journalArticle

Hausenloy, DJ, Erik Botker, H, Condorelli, G, Ferdinándy, P, Garcia-Dorado, D, Heusch, G, Lecour, S, Van Laake, LW, Madonna, R, Ruiz-Meana, M, Schulz, R, Sluijter, JPG, Yellon, DM & Ovize, M 2013, 'Translating cardioprotection for patient benefit: Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology', Cardiovascular Research, vol. 98, no. 1, pp. 7-27. https://doi.org/10.1093/cvr/cvt004
Hausenloy, Derek J. ; Erik Botker, Hans ; Condorelli, Gianluigi ; Ferdinándy, P. ; Garcia-Dorado, David ; Heusch, Gerd ; Lecour, Sandrine ; Van Laake, Linda W. ; Madonna, Rosalinda ; Ruiz-Meana, Marisol ; Schulz, Rainer ; Sluijter, Joost P G ; Yellon, Derek M. ; Ovize, Michel. / Translating cardioprotection for patient benefit : Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. In: Cardiovascular Research. 2013 ; Vol. 98, No. 1. pp. 7-27.
@article{d00d6c0fbbcc4bc48374fb60fe4d6fd2,
title = "Translating cardioprotection for patient benefit: Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology",
abstract = "Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Despite current therapy, the morbidity and mortality for patients with CHD remains significant. The most important manifestations of CHD arise from acute myocardial ischaemia-reperfusion injury (IRI) in terms of cardiomyocyte death and its long-term consequences. As such, new therapeutic interventions are required to protect the heart against the detrimental effects of acute IRI and improve clinical outcomes. Although a large number of cardioprotective therapies discovered in pre-clinical studies have been investigated in CHD patients, few have been translated into the clinical setting, and a significant number of these have failed to show any benefit in terms of reduced myocardial infarction and improved clinical outcomes. Because of this, there is currently no effective therapy for protecting the heart against the detrimental effects of acute IRI in patients with CHD. One major factor for this lack of success in translating cardioprotective therapies into the clinical setting can be attributed to problems with the clinical study design. Many of these clinical studies have not taken into consideration the important data provided from previously published pre-clinical and clinical studies. The overall aim of this ESC Working Group Cellular Biology of the Heart Position Paper is to provide recommendations for optimizing the design of clinical cardioprotection studies, which should hopefully result in new and effective therapeutic interventions for the future benefit of CHD patients.",
keywords = "Acute myocardial infarction, Cardiac surgery, Cardioprotection: Ischaemia, Reperfusion",
author = "Hausenloy, {Derek J.} and {Erik Botker}, Hans and Gianluigi Condorelli and P. Ferdin{\'a}ndy and David Garcia-Dorado and Gerd Heusch and Sandrine Lecour and {Van Laake}, {Linda W.} and Rosalinda Madonna and Marisol Ruiz-Meana and Rainer Schulz and Sluijter, {Joost P G} and Yellon, {Derek M.} and Michel Ovize",
year = "2013",
month = "4",
day = "1",
doi = "10.1093/cvr/cvt004",
language = "English",
volume = "98",
pages = "7--27",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Translating cardioprotection for patient benefit

T2 - Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology

AU - Hausenloy, Derek J.

AU - Erik Botker, Hans

AU - Condorelli, Gianluigi

AU - Ferdinándy, P.

AU - Garcia-Dorado, David

AU - Heusch, Gerd

AU - Lecour, Sandrine

AU - Van Laake, Linda W.

AU - Madonna, Rosalinda

AU - Ruiz-Meana, Marisol

AU - Schulz, Rainer

AU - Sluijter, Joost P G

AU - Yellon, Derek M.

AU - Ovize, Michel

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Despite current therapy, the morbidity and mortality for patients with CHD remains significant. The most important manifestations of CHD arise from acute myocardial ischaemia-reperfusion injury (IRI) in terms of cardiomyocyte death and its long-term consequences. As such, new therapeutic interventions are required to protect the heart against the detrimental effects of acute IRI and improve clinical outcomes. Although a large number of cardioprotective therapies discovered in pre-clinical studies have been investigated in CHD patients, few have been translated into the clinical setting, and a significant number of these have failed to show any benefit in terms of reduced myocardial infarction and improved clinical outcomes. Because of this, there is currently no effective therapy for protecting the heart against the detrimental effects of acute IRI in patients with CHD. One major factor for this lack of success in translating cardioprotective therapies into the clinical setting can be attributed to problems with the clinical study design. Many of these clinical studies have not taken into consideration the important data provided from previously published pre-clinical and clinical studies. The overall aim of this ESC Working Group Cellular Biology of the Heart Position Paper is to provide recommendations for optimizing the design of clinical cardioprotection studies, which should hopefully result in new and effective therapeutic interventions for the future benefit of CHD patients.

AB - Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Despite current therapy, the morbidity and mortality for patients with CHD remains significant. The most important manifestations of CHD arise from acute myocardial ischaemia-reperfusion injury (IRI) in terms of cardiomyocyte death and its long-term consequences. As such, new therapeutic interventions are required to protect the heart against the detrimental effects of acute IRI and improve clinical outcomes. Although a large number of cardioprotective therapies discovered in pre-clinical studies have been investigated in CHD patients, few have been translated into the clinical setting, and a significant number of these have failed to show any benefit in terms of reduced myocardial infarction and improved clinical outcomes. Because of this, there is currently no effective therapy for protecting the heart against the detrimental effects of acute IRI in patients with CHD. One major factor for this lack of success in translating cardioprotective therapies into the clinical setting can be attributed to problems with the clinical study design. Many of these clinical studies have not taken into consideration the important data provided from previously published pre-clinical and clinical studies. The overall aim of this ESC Working Group Cellular Biology of the Heart Position Paper is to provide recommendations for optimizing the design of clinical cardioprotection studies, which should hopefully result in new and effective therapeutic interventions for the future benefit of CHD patients.

KW - Acute myocardial infarction

KW - Cardiac surgery

KW - Cardioprotection: Ischaemia

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=84875170063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875170063&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvt004

DO - 10.1093/cvr/cvt004

M3 - Article

VL - 98

SP - 7

EP - 27

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -